Bridgebio Oncology Therapeutics, Inc. (BBOT) — SEC Filings
Bridgebio Oncology Therapeutics, Inc. (BBOT) — 28 SEC filings. Latest: EFFECT (May 5, 2026). Includes 10 8-K, 6 10-Q, 6 SC 13G.
View Bridgebio Oncology Therapeutics, Inc. on SEC EDGAR
Overview
Bridgebio Oncology Therapeutics, Inc. (BBOT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 26, 2026: BridgeBio Oncology Therapeutics, Inc. announced on March 24, 2026, the departure of Dr. Jonathan B. Lim from his role as Chief Medical Officer. The company also appointed Dr. Michael M. Morrissey as the new Chief Medical Officer, effective March 24, 2026. Dr. Morrissey will receive an annual base sa
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 27 neutral, 1 mixed. The dominant filing sentiment for Bridgebio Oncology Therapeutics, Inc. is neutral.
Filing Type Overview
Bridgebio Oncology Therapeutics, Inc. (BBOT) has filed 1 EFFECT, 10 8-K, 6 10-Q, 2 S-1, 1 10-K, 6 SC 13G, 2 S-1/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of BBOT's 20 recent filings, 2 were flagged as high-risk, 5 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | Not Disclosed |
| EPS | Not Disclosed |
| Debt-to-Equity | N/A |
| Cash Position | Not Disclosed |
| Operating Margin | N/A |
| Total Assets | Not Disclosed |
| Total Debt | $0 |
Key Executives
- Dr. Jonathan B. Lim
- Dr. Michael M. Morrissey
- Eli Wallace
- Maggie L. Wong
- Jocelyn M. Arel
- 857-702-0370
- Joel L. Rubinstein
- Christian O. Nagler
- Anthony J. Zangrillo
Industry Context
BridgeBio Oncology Therapeutics operates in the highly competitive oncology therapeutics sector, focusing on genetically defined cancers driven by RAS and PI3K mutations. The industry is characterized by rapid innovation, significant R&D investment, and a complex regulatory pathway. Key trends include precision medicine, targeted therapies, and the increasing understanding of cancer genomics, which BridgeBio aims to leverage with its small molecule inhibitors.
Top Tags
8-K (5) · SPAC (5) · 10-Q (4) · Helix Acquisition Corp. II (4) · filing (3) · Blank Check Company (3) · spac (3) · S-1 Filing (2) · disclosure (2) · quarterly-report (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Annual Base Salary | $450,000 | For the new Chief Medical Officer, Dr. Michael M. Morrissey. |
| Shares of Common Stock | 63,054,549 | Total shares registered for sale by Selling Securityholders, indicating potential market overhang. |
| PIPE Shares | 24,343,711 | Shares issued in a private placement on February 28, 2025, part of the registered shares. |
| Option Exercise Price Range | $1.02 to $7.88 | Range for the 1,907,207 shares issuable upon exercise of stock options. |
| Closing Date | August 11, 2025 | Date of the Business Combination between Helix and TheRas. |
| Business Combination Agreement Date | February 28, 2025 | Initial date of the agreement for the Business Combination. |
| Closing Price Date | August 28, 2025 | Date when BBOT's common stock closed at $9.45 per share on Nasdaq. |
| Prevalence of RAS mutations | 30% | Approximate percentage of all human cancers driven by RAS mutations. |
| Commission File Number | 001-41955 | Identifies the company's SEC filing history. |
| Film Number | 251187471 | Internal SEC processing number for the filing. |
| Revenue | $0 | No revenue reported for the quarter ended June 30, 2025, consistent with SPAC status. |
| Class A ordinary share par value | $0.0001 | The nominal value of each Class A ordinary share. |
| Standard Industrial Classification (SIC) | 2834 | Indicates the company's target industry is Pharmaceutical Preparations. |
| Fiscal Year End | 1231 | The company's fiscal year ends on December 31st. |
| SEC File Number | 001-41955 | Identifies the company's filings with the SEC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Bridgebio Oncology Therapeutics, Inc. (BBOT)?
Bridgebio Oncology Therapeutics, Inc. has 28 recent SEC filings from Jan 2024 to May 2026, including 10 8-K, 6 10-Q, 6 SC 13G. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BBOT filings?
Across 28 filings, the sentiment breakdown is: 27 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Bridgebio Oncology Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Bridgebio Oncology Therapeutics, Inc. (BBOT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Bridgebio Oncology Therapeutics, Inc.?
Key financial highlights from Bridgebio Oncology Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BBOT?
The investment thesis for BBOT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Bridgebio Oncology Therapeutics, Inc.?
Key executives identified across Bridgebio Oncology Therapeutics, Inc.'s filings include Dr. Jonathan B. Lim, Dr. Michael M. Morrissey, Eli Wallace, Maggie L. Wong, Jocelyn M. Arel and 4 others.
What are the main risk factors for Bridgebio Oncology Therapeutics, Inc. stock?
Of BBOT's 20 assessed filings, 2 were flagged high-risk, 5 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Bridgebio Oncology Therapeutics, Inc.?
Forward guidance and predictions for Bridgebio Oncology Therapeutics, Inc. are extracted from SEC filings as they are enriched.